EBR Systems Press Release

SUNNYVALE, Calif. -- EBR Systems, Inc., developer of the world’s only leadless left ventricular endocardial pacing (LVEP) system for heart failure, today announced its participation in the Heart Rhythm 2026 conference, taking place April 23-26, 2026, in Chicago, IL.

EBR will have a strong presence at the conference, including an exhibit booth showcasing the WiSE® System and participation in multiple scientific sessions. The following talks are sponsored by EBR:

Real World Experience with the WiSE System: Early Post-Approval US Practice and Outcomes
Presenter: Dr. Niraj Varma
Friday 24 April, 11:30 AM-11:40 AM CT
Heart Rhythm Hub 3 – South Lobby, McCormick Place

Lunch Symposium: Getting WiSE with Leadless LV Endocardial Pacing
Moderator: Dr. Robert Canby
Presenters: Dr. David Slotwiner, Dr Devi Nair, Dr Niraj Varma
Friday 24 April, 12:00 PM-13:30 PM CT
McCormick Place, Meeting Room S105

“Our presence at Heart Rhythm 2026 comes at a pivotal time for EBR. Since receiving our FDA approval for the WiSE System in April 2025, we’ve completed our first commercial implants in the U.S., received New Technology Add-On Payment (NTAP) and Transitional Pass-Through (TPT) reimbursement, and successfully began enrolling patients in the WiSE-UP post-approval study. This year’s Heart Rhythm conference is an exciting opportunity to demonstrate how EBR is advancing cardiac resynchronization therapy to deliver better results to patients,” said John McCutcheon, President and CEO of EBR Systems.

About EBR Systems

EBR Systems is a cardiac rhythm management company on a clear mission: to transform the lives of people with heart failure by helping physicians deliver optimal cardiac pacing. The WiSE System—the first FDA approved system for leadless left ventricular endocardial pacing (LVEP) in CRT—combines advanced engineering with peer-reviewed clinical evidence to expand access for patients who previously lacked options and to improve outcomes.

EBR Systems’ WiSE Technology

The WiSE System delivers LV endocardial pacing without a transvenous LV lead using targeted ultrasound. A subcutaneous transmitter and battery detect the RV pacing signal and, within milliseconds, emit ultrasound energy that a rice-sized endocardial electrode converts into an electrical pulse—enabling synchronized biventricular pacing. This LVEP approach is engineered for versatility across patient anatomies and is supported by peer-reviewed outcomes from SOLVE-CRT pivotal trial. WiSE is approved for commercial use in the United States and limited to clinical study use outside of the United States.